Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FTC Hits Delay In Approving Aussie CSL’s Buy Of Talecris

This article was originally published in PharmAsia News

Executive Summary

A delay by a U.S. agency is expected to add several months to Australia-based CSL's $3.1 billion acquisition of Talecris Biotherapeutics Holdings. The U.S. Federal Trade Commission has asked for more information about the merger of CSL, the second-largest supplier of blood-plasma products, and U.S.-based Talecris, maker of key treatments for autoimmune diseases. The FTC is supposed to respond within 30 days to merger plans, but a CSL spokeswoman said the review process is now expected to take longer, but before August and the anniversary of the acquisition proposal. The deal hinges on agency approval within 12 months of the offer, and if not met, requires a $75 million fee to the venture company owners of Talecris. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069864

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel